Online citations, reference lists, and bibliographies.

Fasting Blood Glucose Level In Locally Advanced Non-Small Cell Lung Cancer: A New Prognostic Factor?

Esra Korkmaz Kıraklı, Ufuk Yılmaz, Hasan Yılmaz, Berna Komurcuoglu
Published 2018 · Medicine, Biology
Cite This
Download PDF
Analyze on Scholarcy
Share
Hyperglycemia may lead to proliferation, invasion, apoptosis inhibition, migration, and eventually metastasis of cancer cells by several mechanisms. In this study, the effect of hyperglycemia on overall survival (OS), disease-free survival (DFS), and locoregional recurrence (LRR) was investigated in NSCLC. One stage IIIA-IIIB NSCLC patient treated with chemoradiotherapy between 2010 and 2015 was enrolled. Fasting blood glucose (FBG) levels were recorded in pre-treatment, treatment, and post-treatment periods. Median age was 54 years (51–62). Fifty-two patients had squamous cell carcinoma (SCC); 19 had adenocarcinoma. Median follow-up was 19 (11–30), median survival was 19 (13–24), and DFS was 9 (7–11) months. Diabetic patients had shorter survival than non-diabetics 12 (95%CI, 10–14) vs. 25 months (95%CI,18–32), p = 0.005. Number of patients with LRR was also higher in diabetics compared to non-diabetics (8/12 vs. 11/37, p = 0.039). OS was shorter in patients with hyperglycemic-FBG and diabetic-FBG levels in pre-treatment period (log-rank p = 0.03 and 0.023, respectively). Diabetic-FBG level in pre-treatment period was found to be the only independent risk factor for survival. In subgroup analysis, these differences were apparent in SCC (log-rank p = 0.009 for hyperglicemic, log-rank p = 0.017 for diabetic-FBG). LRR was 68% in patients with diabetic-FBG, 36.5% in patients with non-diabetic-FBG in post-treatment period (p = 0.015). Patients with LRR had significantly higher median FBG value in post-treatment period compared to non-relapsing patients, 138 mg/dL (119–228) and 111 mg/dL (99–164), respectively (p = 0.022). The patients with hyperglycemic and diabetic-FBG levels in pre-treatment period had shorter survival compared to normoglycemic ones. The patients with diabetic-FBG level in post-treatment period had higher LRR, and relapsing patients had higher FBG levels in post-treatment period.
This paper references
10.1371/journal.pone.0065945
Analysis of Epigenetic Factors in Mouse Embryonic Neural Stem Cells Exposed to Hyperglycemia
Sukanya Shyamasundar (2013)
10.1158/0008-5472.CAN-06-1501
Cancer's molecular sweet tooth and the Warburg effect.
Jung-whan Kim (2006)
10.1001/jama.2008.824
Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis.
Bethany B. Barone (2008)
10.1016/j.ygyno.2015.09.004
Does diabetes mellitus have an impact on the prognosis for patients with cervical cancer?
Jeong in Choi (2015)
10.1002/ijc.22717
Diabetes mellitus and risk of breast cancer: a meta-analysis.
Susanna C. Larsson (2007)
10.2337/diacare.26.11.3160
Follow-up report on the diagnosis of diabetes mellitus.
Saul M. Genuth (2003)
10.1007/s10620-009-0944-8
Colorectal Cancer Outcomes, Recurrence, and Complications in Persons With and Without Diabetes Mellitus: A Systematic Review and Meta-Analysis
Kelly B. Stein (2009)
10.3322/caac.20078
Diabetes and cancer: a consensus report.
Edward L. Giovannucci (2010)
10.1038/ncponc0062
Therapy Insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer
Lisa C. Richardson (2005)
10.1245/s10434-009-0789-6
Preoperative Diabetes Mellitus and Long-Term Survival After Resection of Pancreatic Adenocarcinoma
Carrie K. Chu (2009)
10.1002/9781118924853.CH2
Classification and Diagnosis of Diabetes
Ambady Ramachandran (2016)
10.3390/ijms18010023
Cancer’s Achilles’ Heel: Apoptosis and Necroptosis to the Rescue
Atreyi Dasgupta (2016)
10.1016/j.rppneu.2013.09.001
Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?
Ali Inal (2014)
10.1055/s-2008-1081488
Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence.
D. Leroith (2008)
10.1136/bmj.38415.708634.F7
Metformin and reduced risk of cancer in diabetic patients
Josie M. M. Evans (2005)
10.1111/j.1749-6632.2011.06285.x
Diabetes, cancer, and metformin: connections of metabolism and cell proliferation.
Emily J Gallagher (2011)
10.1172/JCI67230
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations.
Gregg L Semenza (2013)
10.1371/journal.pone.0166612
Impact of Hyperglycemia on Outcomes among Patients Receiving Neoadjuvant Chemotherapy for Bulky Early Stage Cervical Cancer
Jing Li (2016)
10.4158/EP.12.4.358
Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients.
Amy Calabrese Donihi (2006)
10.2337/diacare.25.2007.s5
Report of the expert committee on the diagnosis and classification of diabetes mellitus.
James R Gavin (2003)
10.1007/s11060-015-1815-0
Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide
Minh Thi Tieu (2015)
( NSCLC ) patients
A Inal (2014)
10.1016/j.lungcan.2011.07.019
Confirmation of the role of diabetes in the local recurrence of surgically resected non-small cell lung cancer.
John Michael Varlotto (2012)
Patients with diabetes-induced microangiopathy show a reduced frequency of carcinomas.
Andreas G. Nerlich (1998)
10.1371/journal.pone.0105550
Hyperglycemia Promotes K-Ras-Induced Lung Tumorigenesis through BASCs Amplification
Carla Micucci (2014)
10.1001/archinte.160.14.2217
Diabetes is associated with longer survival rates in patients with malignant tumors.
Roberto De Giorgio (2000)
10.1016/j.critrevonc.2005.04.008
Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach.
M. L. G. Janssen-Heijnen (2005)
10.1186/s12885-015-2012-4
Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer
Hisao Imai (2015)
10.1016/S0084-3873(11)00370-1
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
Sven Schinner (2011)
Transforming growth factor beta, fibrogenesis and hyperglycemia in patients with chronic pancreatitis.
Paola Fogar (1998)
10.1136/bmj.g7707
Type 2 diabetes and risk of cancer
Ambika Satija (2015)
10.1001/archinte.167.5.513-a
Protective effect of diabetes against metastasis in patients with non-small cell lung cancer.
Amr Hanbali (2007)
10.1093/annonc/mdw410
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
C. Coyle (2016)
10.1200/JCO.2010.29.3183
Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer.
Kirsten Erickson (2011)
10.2337/dc17-s005
2. Classification and Diagnosis of Diabetes
(2016)
Isıkdogan A (2014) Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung
A Inal (2013)
10.2967/jnumed.108.054205
18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response*
Simona Ben-Haim (2009)
10.1002/ijc.10882
Impact of comorbidity on lung cancer survival.
C. Martin Tammemagi (2003)
10.1097/ALN.0b013e3181799d45
Obesity-induced Insulin Resistance and Hyperglycemia: Etiologic Factors and Molecular Mechanisms
Jeevendra J. A. Martyn (2008)
10.1155/2012/639469
Fisetin Inhibits Hyperglycemia-Induced Proinflammatory Cytokine Production by Epigenetic Mechanisms
Hye Joo Kim (2012)
10.1128/MCB.21.17.5899-5912.2001
Growth Factors Can Influence Cell Growth and Survival through Effects on Glucose Metabolism
Matthew G. Vander Heiden (2001)
10.4137/CMO.S6916
Relationship Between Plasma Glucose Levels and Malignant Uterine Cervical Neoplasias
Rosekeila Simões Nomelini (2011)
10.3322/caac.21387
Cancer Statistics, 2017.
Rebecca L Siegel (2017)
10.1093/annonc/mdt367
Diabetes in relation to breast cancer relapse and all-cause mortality in elderly breast cancer patients: a FOCUS study analysis.
Mandy Kiderlen (2013)
10.1038/bjc.2013.187
Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK
Yaryna Storozhuk (2013)
10.1128/AEM.01703-10
Deletion or Overexpression of Mitochondrial NAD+ Carriers in Saccharomyces cerevisiae Alters Cellular NAD and ATP Contents and Affects Mitochondrial Metabolism and the Rate of Glycolysis
Gennaro Agrimi (2011)
10.1200/JCO.2009.27.3011
Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis.
Kimberly S. Peairs (2011)
10.3322/caac.20006
Cancer statistics, 2009.
Ahmedin Jemal (2009)
10.1073/pnas.1003428107
Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity
Frank Weinberg (2010)
A (2017) Cancer Statistics, 2017
RL Siegel (2017)
On the origin of cancer cells.
Otto Heinrich Warburg (1956)
10.1016/j.lungcan.2011.10.019
Fasting blood glucose level and prognosis in non-small cell lung cancer (NSCLC) patients.
Juhua Luo (2012)
10.1007/s12032-012-0367-9
Survival difference in NSCLC and SCLC patients with diabetes mellitus according to the first-line therapy
Kensuke Nakazawa (2013)
10.1158/1535-7163.MCT-12-0131
A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo
Yi Liu (2012)
10.1097/JTO.0b013e31822a75be
Prolonged Survival in Patients with Lung Cancer with Diabetes Mellitus
Peter Hatlen (2011)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar